Hematopathology Fellowship Program

 Trainee Scholarly Activities

 

PEER-REVIEWED

  1. NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma. Murga-Zamalloa CA, Mendoza-Reinoso V, Sahasrabuddhe AA, Rolland D, Hwang SR, McDonnell SR, Sciallis AP, Wilcox RA, Bashur V, Elenitoba-Johnson K, Lim MS. Oncogene. 2017 Apr;36(15):2085-2094. PMID: 27694894. 2017 Benjamin Castleman Award, United States and Canadian Academy of Pathology.
  2. T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. Wang T, Lu Y, Polk A, Chowdhury P, Murga-Zamalloa C, Fujiwara H, Suemori K, Beyersdorf N, Hristov AC, Lim MS, Bailey NG, Wilcox RA. Clin Cancer Res. 2017 May 15;23(10):2506-2515.
  3. Multimodal laser-based angioscopy for structural, chemical and biological imaging of atherosclerosis. Savastano LE, Zhou Q, Smith A, Vega K, Murga-Zamalloa C, Gordon D, McHugh J, Zhao L, Wang M, Pandey A, Thompson BG, Xu J, Zhang J, Chen YE, Seibel EJ, Wang TD. Nat Biomed Eng. 2017;1. (In press) PMID: 28555172.
  4. Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. Hwang SR, Murga-Zamalloa C, Brown N, Basappa J, McDonnell SR, Mendoza-Reinoso V, Basrur V, Wilcox R, Elenitoba-Johnson K, Lim MS. Lab Invest. 2017 Apr 17 (In press). PMID: 28414323.
  5. Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Carlos Murga-Zamalloa, Avery Polk, Hanel Walter, Pinki Chowdhury, Noah Brown, Alexandra C. Hristov, Nathanael G. Bailey, Tianjiao Wang, Tycel Phillips, Sumana Devata, Pradeep Poonnen, Juan Gomez-Gelvez, Kedar V. Inamdar and Ryan A. Wilcox. 2017 Blood (under review).
  6. Hathuc V, Hristov A, Smith L. Primary Cutaneous Acral CD8+ T cell lymphoma. Archives of Pathology and Laboratory Medicine (Accepted for publication)
  7. Charles NJ, Boyer DF.  Mixed Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls.    Arch Pathol Lab Med.  In press.
  8. Coffing BN, Lim MS. "Signet ring cell lymphoma in a patient with elevated CA-125". J Clin Oncol 2011; 29:416-418. PMID: 21383298
  9. Wey E & Smith LB (2011). "Anaplastic large cell lymphoma (monomorphic PTLD) presenting in gallbladder". Journal of Hematopathology, 4, 17-20.
  10. Hummel JM, Thorland EC, Lim MS. Hodgkin lymphoma in a young child contributing to a diagnosis of ataxia telangiectasia: review of the literature. J Hematop 2010; 3:69-76.
  11. Hummel JM, Frias-Kletecka M, Sanks J, Chiselite M, Roulston D, Smith LB, Czuchlewski DR, Foucar K, Elenitoba-Johnson KSJ, Lim MS. Concomitant BCR-ABL translocation and JAK2V617F mutation in three patients with myeloproliferative neoplasms. (manuscript submitted)
  12. Mankey CC, Coffing BN, Wey EA, Mongia S, McNeil C, Thomas DG, Keyoumarsi F, Elenitoba-Johnson KSJ, Lim MS. Receptor tyrosine kinase profiling identifies RON tyrosine kinase in Hodgkin and non-Hodgkin lymphoma. (manuscript submitted)
  13. Chiselite MD, Basrur V, Conlon KP, Fermin D, Teruya-Feldstein JT, Waxman I, Cairo MS, Elenitoba-Johnson KSJ, Lim MS. "L-plastin (lymphocyte cytosolic protein 1) is highly expressed in primary mediastinal large B-cell lymphoma and is selectively lost in the tumor cells of a significant subset of classical Hodgkin lymphoma". (manuscript submitted)
  14. Lim MS, Miles RR, Elenitoba-Johnson KSJ. (2010) Molecular Pathology of Hematolymphoid Diseases (Dunphy CH ed) Springer Science+Business Media. Proteomics of Human Malignant Lymphoma.
  15. Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, Basrur V, Elenitoba-Johnson KSJ, Hess JL. "The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis". Cancer Cell. 2010;17(6):609-21.PMID: 20541477
  16. Ding H, Gabali AM, Jenson SD, Lim MS, Elenitoba-Johnson KS. "P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas". J Hematop 2009; 2:195-204. PMID: 20309428
  17. Miles RR, Mankey CC, Seiler CE 3rd, Smith LB, Teruya-Feldstein J, Hsi ED, Elenitoba-Johnson KS,
    Lim MS. "Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas".  Hum Pathol 2009; 40:1731-1737. PMID: 19716163
  18. Lim MS, Miles RM, Elenitoba-Johnson KSJ (2009) Proteomics of hematologic malignancies (C. Dunphy ed.) Springer Molecular Hematopathology
  19. Hall, Diane A.; Pu, Robert T. (2008). "Acinic cell carcinoma of the salivary gland: A Continuing Medical Education Case." Diagnostic Cytopathology 36(6): 379-387. http://hdl.handle.net/2027.42/58660
  20. Sitwala, K.V., Dandekar, M.N., Hess, J.L.  "Hox proteins and leukemia".  Intl J Clin and Exp Path 1:461-74, 2008.
  21. Wey, EA, McDonnell SRP, Thomas D, Elenitoba-Johnson SJ, Lim MS.  Evaluation of Functional GSK-3beta-CDC25A Axis in Hodgkin and Non-Hodgkin Lymphomas. (manuscript in preperations)
  22. Ivan, E, Dobrowolska H, Gill K, Serban G, Li Q, Savage D, Suciu-Foca N, Alobeid B, Bhagat G., Colovai A.,  “The immune Inhibitory Receptor ILT3 is a Reliable Marker for Acute Myeloid Leukemia With Monocytic Differentation”. (submitted for publication)

NON-PEER-REVIEWED/WEB ARTICLES ABSTRACTS

  1. Role of the Colony-Stimulator Factor-1 Receptor (CSF1R) T-cell Lymphoma Progression.  Carlos Murga-Zamalloa, Avery Polka, Noah Brown, Nathaniel Bailey, Ryan Wilcox. United States and Canadian Academy of Pathology (USCAP), San Antonio, USA (2017). 2017 Stowell-Orbison Award, Annual USCAP Meeting.
  2. Hathuc V, Smith L. 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. New Frontiers in Diagnostic Pathology conference 2016, Ann Arbor, MI.
  3. Hathuc V, Walkovich K, Bixby D, Smith L. Familial Acute Myeloid Leukemia/Myelodysplastic Syndrome with Germline RUNX1 Mutations: A Single Institution Experience.  United States and Canadian Academy of Pathology meeting 2017, San Antonio, TX.
  4. Hathuc V, East E, Pang J, Jorns J, Dewar R. A Practical Quality Control Procedure for Decalcified Bone Specimens in Evaluation of ER/PR/HER-2 Immunohistochemistry. United States and Canadian Academy of Pathology meeting 2017, San Antonio, TX.
  5. Miles RR, Waxman I, van de Ven C, Ayello JP, Day NS, Lim MS, Basrur V, Conlon KP, Elenitoba-Johnson KSJ, Perkins SL, Cairo MS. Bortezomib (BTZ), IKK inhibitor ML120B, and combination therapy induce apoptosis, inhibit NF-κB activation, and decrease specific proteins in primary mediastinal B-cell lymphoma (PMBL). Accepted for oral presentation at 11th International Conference on Malignant Lymphoma, Jun 2011
  6. Gabali AM, Keyoumarsi F, Thomas DG, Elenitoba-Johnson KSJ, Lim MS. Downregulation of A20 tumor suppressor gene product in classical Hodgkin lymphomas and subtypes of non-Hodgkin lymphomas. United States and Canadian Academy of Pathology Annual Meeting, Feb 2011
  7. Brown NA, McNeil C, Basrur V, Fermin D, Conlon K, Rolland D, van den Berg A, Poppema S, Elenitoba-Johnson KSJ, Lim MS. Mass spectrometry-based glycoproteomic profiling identifies distinct protein biomarkers of Hodgkin lymphoma. United States and Canadian Academy of Pathology Annual Meeting, Feb 2011
  8. Wey EA, Laliberte J, McNeil C, Basrur V, Keyoumarsi F, Thomas DG, Suh C, Huh J, Elenitoba-Johnson KSJ, Lim MS. Expression of B7-H3 (CD276) an immunoregulatory cell surface molecule in non-Hodgkin lymphomas identified by mass spectrometry. United States and Canadian Academy of Pathology Annual Meeting, Feb 2011
  9. Hummel J, Lim MS. Pediatric mycosis fungoides. T-Cell Lymphoma Forum, Jan 2011
  10. Day NS, Ayello J, Miles RR, Perkins SL, Lim MS, Waxman I, van de Ven C, Sanger WG, Harrison L, Goldman S, Cairo MS. Comparative genomic identification of unique signaling pathways and targets in pediatric Burkitt lymphoma (PBL). 52nd American Society of Hematology Annual Meeting, Dec 2010
  11. Hummel JM, Frias-Kletecka M, Sanks J, Chiselite M, Roulston D, Smith LB, Czuchlewski DR, Foucar K, Elenitoba-Johnson KSJ, Lim MS. Concomitant BCR-ABL translocation and JAK2V617F mutation in three patients with myeloproliferative neoplasms. (manuscript submitted)
  12. Brown N, Schnitzer B & Smith LB. Elderly Hodgkin Lymphoma. 2010 ASCP annual meeting. San Francisco, CA. 10/2010.
  13. Chiselite M, Schnitzer B, Roulston D & Smith LB. Indolent mantle cell lymphoma. European Association of Hematopathology meeting. Uppsala, Sweden, September 30, 2010.
  14. Hummel J, Sanks J, Chiselite M, Smith LB, Elenitoba-Johnson KSJ, Lim MS. Concomitant BCR-ABL translocation and JAK2 V617F mutation in myeloproliferative disorders. American Society for Investigative Pathology Annual Meeting, Apr 2010.
  15. McDonnell S, Wey E, Cheng M, Zeng Z, Zu Y, Elenitoba-Johnson KSJ, Lim MS. NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis. American Society for Investigative Pathology Annual Meeting, Apr 2010
  16. Coffing B, Mankey CC, Wey EA, Mongia S, McNeil C, Thomas DG, Keyoumarsi F, Elenitoba-Johnson KSJ, Lim MS. Receptor tyrosine kinase profiling identifies RON tyrosine kinase in Hodgkin and non-Hodgkin lymphoma. United States and Canadian Association of Pathology Annual Meeting, Washington, DC, Mar 2010
  17. Wey E, Mankey C, McDonnell S, Kronk A, Thomas D, Keyoumarsi F, Elenitoba-Johnson KSJ, Lim MS. Evaluation of functional GSK-3β-Cdc25A axis in Hodgkin and non-Hodgkin lymphomas. United States and Canadian Association of Pathology Annual Meeting, Washington, DC, Mar 2010
  18. Muntean, A., Tan, J., Sitwala, K., Monroe, S., Dandekar, M., Huang, Y., Robertson, G., Hero, A., Hess, J.L. Mechanisms of Transformation by MLL Fusion Proteins.  FASEB Summer Research Conference on Hematologic Malignancies.  Saxtons River, VT, August 2-7, 2009.
  19. Hall DA, Finn WG, and Ross CW. Monomorphic post-transplant lymphoproliferative disorder, plasmacytoma-like.  Society for Hematopathology and European Association for Haematopathology Workshop, Cleveland Clinic, September 24-26, 2009.
  20. Sitwala KV and Ross CW.  Plasmablastic lymphoma.  Society for Hematopathology and European Association for Hematopathology Workshop, Cleveland Clinic, September 24-26, 2009.
  21. Wey E, De J, & Smith LB. Diffuse large B cell lymphoma with plasmacytic differentiation. Society for hematopathology workshop, Cleveland, 9/2009.
  22. Hummel J, Utiger C & Smith LB. IgM myeloma. Society for hematopathology workshop, Cleveland, 9/2009.
  23. Miles RR & Smith LB. Plasmacytoma-like post-transplant lymphoproliferative disorder. Society for hematopathology workshop, Cleveland, 9/2009.
  24. De J, Brown RE, Smith L. A Tissue Microarray based approach to Phosphospecific Analysis of Intracellular Signaling Pathways in Classical Hodgkin Lymphoma. 100th Annual Meeting of the American Association of Cancer Research, Denver, Apr 2009.
  25. Chiselite MD, Teruya-Feldstein J, Elenitoba-Johnson KSJ Lim MS. Differential expression of L-plastin in primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma (HL). United States and Canadian Association of Pathology Annual Meeting, 2009
  26. Gabali A, Lim MS, Elenitoba-Johnson KSJ. Distinct interaction networks of the MUM1/IRF4 in B- and T-cell lymphomas identified by tandem mass spectrometry. American Society of Hematology Meeting, 2009
  27. Hummel J, Hall D, Lim MS. Diagnosis of Hodgkin lymphoma in a young child contributing to a diagnosis of ataxia telangiectasia. College of American Pathologists Annual Meeting, 2009
  28. Mankey CC, Tripp S, Perkins SL, Elenitoba-Johnson KSJ, Lim MS. Expression of B Cell Signaling Proteins (PLC-and Grb2) and EBV status correlate with expression of CD20 In classical Hodgkin lymphoma. United States and Canadian Association of Pathology Annual Meeting, 2009
  29. Hall DA, Schumacher JA, Schnitzer B, Lim MS. Concurrent involvement of the colon by adenocarcinoma and systemic mastocytosis. (manuscript submitted)
  30. Coffing B, Reading SN, Tripp S, Elenitoba-Johnson KSJ, Lim MS. Expression of Phosphorylated Tyrosine Proteins In Bone Marrow Biopsies of Ph Chromic Myeloproliferative Disease (Ph CMPD).  AMP, Grapevine, Texas, November 2008
  31. Miles RR, Seiler CE, Smith LB, Teruya-Feldstin J, Hsi ED, Elenitoba-Johnson KSJ, Lim MS. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. United States and Canadian Association of Pathology, Denver, Mar 2008
  32. Chiselite MD, Fermin D, Basrur V, Conlon KP, Seiler C, Waxman I, Cairo MS, Elenitoba-Johnson KSJ, Lim MS. Quantitative Proteomic Identification of Novel Diagnostic Biomarkers and Therapeutic Targets for Classical Hodgkin Lymphoma. ASH Annual Meeting 2008.
  33. Ivan, E., “Expression of Bone Marrow Stromal Antigen-2 (BST-2, CD317) in B-Cell Lymphomas” accepted for poster presentation during the 2012 USCAP Annual Meeting.
  34. Wey EA, Keyoumarsi F., Smith LB, Thomas D, Elenitoba-Johnson KEJ, Lim MS.  “Expression of Receptor Tyrosine Kinases RON and c-MET in Post-Transplant Lymphoproliferative Disorder.” Abstract to be presented at the United States and Canadian Academy of Pathology, Van Couver, Canada, March 2012.

REVIEW ARTICLES/EDITORIALS

  1. Hummel JM, Thorland EC, Lim MS. Hodgkin lymphoma in a young child contributing to a diagnosis of ataxia telangiectasia: review of the literature. J Hematop 2010; 3:69-76
  2. Wey EA,  McDonald SRP, Hwang SR, Basrur V, Conion KP, Fermin D, Murga-Zamalloa C, Zeng Z, Zu Y, Elenitoba-Johnson KSJ, Lim MS.  “NPM-ALK signals through glycogen synthase kinase 3β to promote Oncogenesis.” Oncogene 2011: doi:10.1038/onc.2011.542. [Epub ahead of print]